Exponent, Inc. (EXPO)
NEUTRALFondamental
65
Prix
$69.78
Capitalisation boursière
$3.39B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$632M
12 derniers mois (au 03/07/2026)
Résultat net
$112M
12 derniers mois (au 03/07/2026)
Flux de trésorerie libre
$122M
Capitaux propres totaux
$390M
Passif total
$387M
Ratio de liquidité général
1.98
Couverture des intérêts
-
Dette/EBITDA
0.62
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$63.65
Prix actuel
$69.78
Marge de sécurité
-9.6%
Fourchette de juste valeur
$45.42 - $81.89
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
31.88
ROE
27.2%
Ratio P/B
11.66
P/FCF
31.00
Marge brute
-
ROIC
20.4%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
20.4%
WACC
8.1%
ROIC − WACC
+12.3 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (18)
- EPS shows upward trend
- Price CAGR 8.82%
- ROIC 20.4%
- Debt/Equity ratio
- Operating Margin 20.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 27.9%
- Revenue Growth 5Y 7.8%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 4.3%
- Earnings Quality (OCF/NI) 1.06
- Share Dilution -0.9%
- Piotroski F-Score 5/9
Échoué (7)
- EPS CAGR 2.16%
- P/FCF 31.00
- P/B Ratio 11.66
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 4.90
- Net Margin Trend 17.7% vs 18.3%
Indisponible (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Catherine Ford Corrigan P.E., Ph.D. | CEO & Director | 56 |
| Mr. Richard L. Schlenker Jr. | Executive VP, Corporate Secretary & Director | 59 |
| Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D. | Group Vice President | 56 |
| Dr. Joseph Rakow Ph.D. | Group Vice President | 48 |
| Dr. Joseph Sala Ph.D. | Group Vice President | 48 |
| Dr. John D. Pye P.E., Ph.D. | President | 54 |
| Dr. Bernard Ross P.E., Ph.D. | Co-Founder & Principal Engineer | - |
| Mr. Eric R. Anderson | Chief Financial Officer | 50 |
| Ms. Gina Flynn | VP of Legal & General Counsel | - |
| Mr. Brian Kundert | Chief Human Resources Officer | 50 |
Risque d'audit
9
Risque du conseil
2
Risque de rémunération
4
Risque droits des actionnaires
2
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for EXPO, sourced from Markets Gazette.